PURDUE PHARMA LP
PharmaPURDUE PHARMA LP is a pharmaceutical company focused on Immunology. Key products include TARGINIQ.
PURDUE PHARMA LP at a Glance
- Fast trial execution (11 months median completion)
PURDUE PHARMA LP's Key Drugs
PURDUE PHARMA LP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PURDUE PHARMA LP's Recent FDA Approvals
New NDA/BLA approvals for PURDUE PHARMA LP over the last two years — novel drugs only, excluding generics and label supplements.
PURDUE PHARMA LP's Therapeutic Areas
PURDUE PHARMA LP's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PURDUE PHARMA LP's Top Competitors
PURDUE PHARMA LP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PURDUE PHARMA LP Pipeline Snapshot
PURDUE PHARMA LP has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 3 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 8/9 completed
- • Speed: 11 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1999-08-05
- Latest
- 2018-09-18
- Applications
- 3
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges